What’s Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to liver failure.
Japan’s Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating profit of 225 billion yen in 2024.
EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares
Alzamend Neuro seals $500,000 Series A Convertible Preferred Stock deal with an investor. Plans to raise up to $25 million for clinical trials and working capital.
Italy Based Stevanato Reports Mixed Q1 Earnings, Revises Annual Guidance On Temporary Destocking
Stevanato Group reports Q1 earnings of 236.0 million euros, down 1% Y/Y. Sales declined due to vial destocking amid pandemic effects. High-value solutions revenue up to 37% driven by syringe demand. Updated FY24 guidance reflects cautious outlook.
Buy Definitive Healthcare Stock On Weakness, Analyst Says As Revised Outlook Appears Achievable
Definitive Healthcare reports Q1 adjusted EPS of $0.08, sales at $63.48M, and adjusted EBITDA of $20 million. Q2 revenue guidance: $62–$63.5 million. FY 2024 revenue outlook: $255–$261 million.
Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease
Google DeepMind reveals its AlphaFold 3, which specializes in molecular predictions for proteins, DNA, RNA, and drug molecules.
Orthopedic Devices Maker Treace Medical Concepts’ Gloomy Forecast Cast Concerns Over Long-Term Viability
Treace Medical Concepts reports Q1 EPS loss of $(0.30), sales hit $51.11 million, up 21%. Surge in procedure kits sold due to expanded surgeon base and product mix shift. FY24 sales guidance adjusted to $201M-$211M. Analysts downgrade, citing competitive challenges.
Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac
Pfizer settles 10,000 Zantac lawsuits over cancer risks, but challenges remain. Details undisclosed. Sanofi's $100 million+ agreement also noted. Legal battles ongoing.
Elanco Animal Health’s Q1 Earnings Show Improved Base Business, Analyst Highlights Slightly Delayed But Encouraging Pipeline
Elanco Animal Health (NYSE: ELAN) reports Q1 results: adjusted EPS $0.34 (-26% Y/Y), sales $1.21B (-4% Y/Y). 2024 guidance: EPS $0.88-$0.96, revenue $4.46-$4.52 billion.
Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher
Results from the Phase 3 SOLARIS trial of TEV-‘749 for schizophrenia treatment. SteadyTeq technology ensures controlled olanzapine release. Clinically meaningful improvements in PANSS scores observed across dosing groups.